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Abstract
This chapter offers literary review of most frequently observed brain tumors in child-
hood. It offers basics of epidemiology, clinical presentation and diagnostics of most often 
occurring types of tumors according to new WHO classification of brain tumors from 
2016 and emphasizes molecular biological characteristics and role of altered genes and 
genetic pathways in brain tumor etiology, classification and treatment. This review not 
only concentrates on gliomas, medulloblastomas and ependymomas, but also offers 
characterization of other less frequently observed lesions. Each tumor characteristics also 
contains basics of therapeutical possibilities of these lesions with focus on targeted and 
individually designed therapy according to molecular and genetic alterations found in 
tumor tissue sample.
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1. Introduction
Brain tumors are the second most common group of tumors (following hematological malig-
nancies) as well as the most frequent solid tumors in childhood [1] in age category up to 
1 year and between 5 and 19 years of age, even the most common childhood malignancy 
[2], as well as the most frequent death cause from all oncological diagnoses [3]. Despite the 
significant progress in imaging and neurosurgical techniques, molecular genetic diagnostics 
and therapeutic protocols as well as the introduction of concomitant chemoradiotherapy, 
cure and survival rates of these children did not significantly change – except for medul-
loblastoma [4].
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
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2. Epidemiology of brain tumors in children
The incidence of pediatric CNS tumors varies worldwide with an average of 4 cases per 
100,000 children with the highest occurrence is in the United States [3]. By age groups, the 
highest incidence is in adolescents (15–19 years, 6.38/100,000), followed by a group of children 
under 1 year (6.2/100,000). Subsequently, it is slightly declining, with 5.5/100,000 children 
aged between 1 and 4 years; in 5–14 years, the incidence is 5.1/100,000 [2, 5]. About 25–30% are 
in supratentorial localization, followed by the cerebellum (15–20%), the brain stem (10–12%), 
the pituitary and suprasellar region (10–15%), cranial nerves (6–7%), brain ventricles (5–6.4%), 
spinal cord (4.3–4.6%) and 2.6–2.9% are tumors of meninges [2, 6], as shown in Figure 1. Also 
a typical localization and histological type occur in certain age group. By 1 year of age, tumors 
most often occur at multiple locations in the brain and in ventricles. At the age of 1–4 years, 
the most common site is the cerebellum, cerebral hemispheres and brain stem. In the age 
range from 5 to 9 years, tumors occur frequently in the cerebellum, brain stem and cerebral 
hemispheres. At the age from birth to 9 years, the most common tumors are gliomas and 
embryonal tumors (up to 1 year is the most common embryonic atypical teratoma/rhabdoid 
tumor (AT/RT), in the older children it is medulloblastoma (MB)). In 10–14 year age group, the 
most typical site is cerebral hemisphere and most frequently occurring are gliomas, tumors of 
the pituitary region and embryonal tumors. Adolescents (aged 15–19 years) most often have 
pituitary tumors, then astrocytomas and neoplastic tumors, but the incidence of meningio-
mas also increases. Typical localizations in this age group are the pituitary and suprasellar 
regions, followed by cerebral hemispheres and cerebellum. In general, brain tumors are more 
common in boys [2, 5].
There are many risk factors for brain tumor development, but to date only some hereditary 
syndromes (type 1 and 2 neurofibromatosis, tuberous sclerosis, Li-Fraumeni syndrome, Gorlin 
syndrome, Turcot syndrome, Cowden syndrome, Rubinstein-Taybi syndrome and hereditary 
retinoblastoma) and ionizing radiation have been verified. Other possible risk factors include: 
a personal history of previous cancer treatment, a family history of the CNS tumor, the parent 
age at the time of conception, the later contact of the child with common childhood infectious 
Figure 1. Localization of CNS tumors in pediatric population [5].
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diseases [7], congenital anomalies [8], higher birth weight and larger head circumference [9]. 
Interestingly, the results of studies suggest lower incidence of CNS tumors in children with 
allergies and asthma [10, 11].
3. Classification of brain tumors in children
The new WHO classification of CNS tumors from 2016 for the first time uses molecular genetic 
characteristics for tumor classification in some cases. In this new edition, some new tumor 
entities appeared, some have been merged while others were excluded. Changes involving 
childhood tumors include: inclusion of epithelial glioblastoma, removal of the term brain 
gliomatosis, reclassification of the diffuse intrinsic pontine glioma to diffuse midline glioma, 
H3 K27–mutant, inclusion of the ependymoma, RELA fusion–positive as a separate unit and 
inclusion of the diffuse leptomeningeal glioneuronal tumor. The change also affected the clas-
sification of medulloblastomas, where genetically defined classification was added. The term 
primitive neuroectodermal tumors (CNS PNET) was eliminated while an embryonal tumor 
with multilayered rosettes, C19MC–altered was included [12].
Childhood brain tumors are also classified according to their localization into: infratentorial, 
supratentorial tumors and tumors of parasellar region. Most frequently observed histological 
types of pediatric CNS tumors are shown in Figure 2.
Infratentorial localization is typical for cerebellar astrocytoma (pilocytic astrocytoma – PA, 
but also diffuse less frequently anaplastic astrocytoma and glioblastoma), medulloblasto-
mas, ependymomas, brain stem gliomas (most commonly diffuse midline glioma, H3 K27– 
mutant, PA), AT/RT and choroid plexus tumors.
Supratentorial localization are common: low-grade glioma—LGG (PA, diffuse astrocy-
toma, oligodendroglioma, mixed oligoastrocytoma, subependymal giant cell astrocytoma— 
SEGA, pleomorphic xanthoastrocytoma—PXA), high-grade glioma—HGG (anaplastic astro-
cytoma, anaplastic oligodendroglioma and glioblastoma), neuronal and mixed neuronal-glial 
Figure 2. Most frequent histological types of CNS tumors in children [5].
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tumors (ganglioglioma—GG, desmoplastic infantile astrocytoma—DIA, ganglioglioma—
DIGG, dysembryoplastic neuroepithelial tumor—DNET and papillary glioneuronal tumor), 
embryonal tumors (embryonal tumor with multilayered rosettes, C19MC-altered—ETMR, 
medulloepithelioma, CNS neuroblastoma, CNS ganglioneuroblastoma, CNS embryonal 
tumor and CNS embryonal tumor with rhabdoid features), AT/RT, ependymomas, menin-
giomas, choroid plexus tumors, pineal tumors (pineocytomas, pineal parenchymal tumor of 
intermediate differentiation and papillary tumors of the pineal region) and rarely metastases 
of extra-neural malignant tumors.
Tumors occurring in parasellar region usually are: craniopharyngiomas, adenomas, LGG 
astrocytomas (tumors of central regions, chiasma, hypothalamus, thalamus, PA or diffuse 
astrocytomas) as well as germ cell tumors.
4. Brain tumors symptoms in children
Symptoms of brain tumors can develop gradually and worsen over time, or they may mani-
fest suddenly and dramatically. Symptoms may be general or specific, resulting from tumor 
localization. General symptoms are manifestation of intracranial hypertension that is caused 
either by tumor growth, brain swelling or onset of hydrocephalus or a combination of these 
factors. Symptoms of intracranial hypertension include: headache (especially in the morning 
after awakening), nausea or vomiting, diplopia and strabismus, disturbances of balance, per-
sonality changes, epileptic seizures or loss of consciousness. Infants may experience irritabil-
ity, loss of appetite, delay or regression of psychomotor development. There is also bulging 
of the fontanelle and the disproportionate enlargement of the head circumference. Children 
of school age may suffer from increased fatigue, psychological changes, impairment of school 
performance, disturbances of memory and impaired concentration. Regarding the localiza-
tion of the tumor, other locally specific neurological symptoms may also occur: visual dis-
turbances, narrowing and outages of visual field, abnormal bulb movements, nystagmus, 
hearing or speech disorders, paresis or hemiparesis, muscle weakness, loss of sensitivity or 
coordination, ataxia, posture disorder, walking instability, tingling of body parts, cranial 
nerves palsy as well as hormonal disorders.
5. Brain tumors diagnostics
Diagnosis of brain tumor is based on a patient history and complete neurological examination. 
Imaging examination is performed when a brain tumor is suspected. Basic imaging examina-
tion is magnetic resonance imaging (MRI). It is the most spectacular imaging for intracra-
nial structures that is currently available in medicine. In brain tumor diagnostics the use of 
contrast media—gadolinium—is essential. MR-angiography displays brain vessels alongside 
with pathological tumor vasculature, what is important for planning of the surgical treat-
ment. MR-spectroscopy is a metabolic examination of the brain. The perfusion MRI monitors 
blood flow in the investigated area. Tumors are metabolically active and require greater blood 
supply. Functional MRI and MR-tractography are used for planning of surgical approach. 
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Preoperatively, the navigational MRI is performed for the needs of intraoperative navigation. 
Among the disadvantages of MRI is relatively longer duration, which in smaller children 
requires general anesthesia. However, a huge advantage is the absence of radiation [13].
Computer tomography (CT) is mostly used for the display of bones and their lesions, which 
do not appear in detail in MRI. Another indication may be CT-angiography. Due to the high 
dose of radiation; however, CT is reserved for cases of sudden changes in the neurological 
condition when rapid imaging is necessary.
Positron emission tomography (PET) uses radioactive fluorodeoxyglucose for visualization 
of tumor tissue that is metabolically more active. The radioactive load is very low and is 
excluded in 1 day. It can be used preoperatively for diagnostics as well as for postoperative 
distinguishing between residues, recurrences and postoperative changes in unclear cases [14].
Angiography (mostly DSA) uses vessel imaging after contrast agent administration to assess 
tumor vascular supply. It is also associated with radiation and though is currently replaced 
by MR- or CT-angiography. However, it remains reserved for preoperative embolization of 
the tumor, which is carried out by DSA [13].
Specimen of CSF obtained from lumbar puncture is used for cytological examination to detect 
the presence of tumor cells that occur in CSF in tumor dissemination or in leukemia tumors. 
It is also used to detect the presence of tumor markers, in particular bHCG and AFP in germ 
cell tumors. It also serves to verify the presence of infection, especially in the postoperative 
period [13].
Biopsy of brain tumor is essential for definitive diagnosis. In most cases, tissue sample is 
obtained during surgery. However, there are also cases of inoperable tumors according to 
their localization or extent. If a tumor resection cannot be performed, a stereotactic biopsy 
can be useful. In some cases, however, the biopsy is too risky, and therefore the diagnosis is 
determined only by MRI (e.g., diffuse pontine gliomas).
Also other examinations could be useful, such as: EEG, evoked potentials, evaluation of neu-
rocognitive functions, ophthalmological examination (papilledema of optic nerve and perim-
eter), evaluation of hearing disorder and hormone levels and function [13].
6. Treatment of brain tumors
Treatment consists of surgical intervention, followed by oncological and symptomatic treat-
ment and requires multidisciplinary approach.
Surgical treatment is the basis of treatment and, in some tumors, it is the only sufficient form 
of therapy. Also histologically, benign tumors can be a surgical challenge by their localiza-
tion. An essential part of brain tumor surgery is the use of microscope and micro instruments. 
Nowadays, it belongs to the usual equipment of surgical department, as well as ultrasonic 
aspirator, navigation systems, intraoperative sonography and possibility of realization of 
electrophysiological monitoring. Electrophysiological monitoring requires appropriate 
instrumentation and personnel equipment that enhances the safety of the operation to the 
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full possible extent in the eloquent areas of the CNS. Use of 5-aminolevulic acid is very help-
ful in operations of HGG. Patient ingests this acid prior to surgery, and then during surgery, 
with use of fluorescence on the microscope, high-grade glial cells begin to gleam, which also 
contributes to performance of accurate resection and representative tumor sampling for his-
tological examination. Awake operations with the possibility of intraoperative stimulation, in 
which the patient is conscious either during the entire procedure or in a certain part of it, are 
used in adult patients, especially in tumors in motor, sensory and speech areas. In children, 
it is significantly limited by age and ability to cooperate. They are mainly performed in older 
age groups of children [15].
According to extent of resection, we divide surgical treatment into: total resection, near-total 
resection, partial resection and biopsy. In most tumors (except well-defined benign tumors 
or well-defined metastases), total resection is only a radiological rather than a biological term. 
The surgical approach can serve (though not as a standard treatment method) for the tar-
geted administration of radiotherapy in the form of intraoperative radiotherapy with a single 
irradiation of the tumor bed directly after resection of the tumor [16] or chemotherapy—for 
example, intraoperative administration of biodegradable carmustine [17]. In addition to cra-
niotomy, other techniques—for example, endonasal trans-sphenoidal approach—can also 
be used, including endoscopy for pituitary tumor tumors. Another option for biopsy or tumor 
removal (often when located in brain ventricles) is endoscopic surgery. From other surgical 
methods, shunts in hydrocephalus can be used, most commonly ventriculoperitoneal shunt. 
Another option is implantation of Ommaya reservoir, which is useful for repeated sampling 
of CSF for laboratory examinations, for therapeutic evacuation puncture of CSF, as well as for 
the local administration of chemotherapy.
Chemotherapy is part of adjuvant oncological treatment after surgical resection alone or along 
with radiotherapy. It can be administered systemically (intravenously or orally), locally dur-
ing surgery, or postoperatively into an implanted reservoir. Most serious side effects of che-
motherapy are: bone marrow depression, nausea, vomiting, diarrhea and temporary hair loss. 
Generally, children better tolerate high doses of chemotherapy compared to adults, which 
may increase the aggressiveness of treatment if necessary.
Targeted biological therapy is directed against the specific protein and gene targets of the 
tumor, or against the environment that affects its growth and survival. But even all tumors of 
the same histological type do not have the same alterations and the treatment goals. Therefore, 
it is essential to examine each tumor sample for the presence of altered genes and proteins in 
order to determine targeted individualized treatment. One of the best known drugs is bevaci-
zumab with an antiangiogenic effect, which stops the nutrient intake into the tumor by blocking 
of angiogenesis. This treatment is used for HGG. However, the effect of this treatment is lower 
than expected. Therefore, it is reserved as supportive treatment in relapsing non-responding 
tumors. Also used is everolimus, the mTOR pathway blocker in the treatment of subependemal 
giant astrocytoma, or tyrosine kinase inhibitors, in particular EGFR (erlotinib and gefitinib) in 
the treatment of ependymomas [18]. Patients with HGG with a proven BRAF V600E mutation 
also receive BRAF inhibitors (vemurafenib and dabrafenib) with partial effects [19].
Radiotherapy is also often used in treatment of pediatric brain tumors, either alone or as part 
of concomitant therapy. It uses high energy RTG beams to damage tumor cell DNA. It can 
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take various forms, using external radiotherapy as well as local forms. External radiotherapy 
is mostly accomplished with a linear accelerator by various techniques, such as conventional 
radiotherapy, 3D conformal radiotherapy, modulated beam intensities, stereotactic radiother-
apy using stereotactic frames or radio-surgical methods (single irradiation) that use a linear 
accelerator, gamma knife or cyber knife as the source of radiation. Local forms of radiother-
apy require an invasive approach. This group includes intraoperative radiotherapy, which is 
applied during surgery and interstitial brachytherapy requiring surgical delivery of emitters 
close to the tumor. Subsequently, radiotherapy is applied in the postoperative period. Local 
forms have, of course, a minor incidence of undesirable radiotherapy effects, of which the 
most common are: fatigue, hair loss, radiation dermatitis, brain edema and presence of post 
radiation necrosis and encephalopathy. Proton therapy is becoming increasingly popular.
The novelty in the treatment of HGG is the use of an alternating electric field. It appears to 
be the most effective in connection to concomitant chemoradiotherapy. It is recommended for 
treatment of recurrent tumors [20].
Very necessary is also supportive medical treatment, in particular corticosteroids which sup-
press perifocal and postoperative edema, anticonvulsants (in the presence of epileptic sei-
zures), analgesics, antiemetic drugs, nutritional support and oncological rehabilitation [21].
7. Most common brain tumor types occurring in childhood
The most common CNS tumors in children are: gliomas, ependymomas, neuroglial tumors, 
embryonal tumors, choroid plexus tumors, craniopharyngiomas and germ cell tumors.
7.1. Gliomas
Glial tumors account for 55% of pediatric CNS tumors [3]. It is a heterogeneous group of 
tumors that varies from a well-defined, potentially curable low-grade pilocytic astrocy-
toma and diffusely growing astrocytomas (grade II) to high-grade, aggressive and incurable 
tumors, such as diffuse glioma of midline structures. They arise from CNS glial precursor 
cells: astrocytomas originate in astrocytes, oligodendrogliomas in oligodendrocytes, mixed 
gliomas are derived from astrocytes, oligodendrocytes and ependymal cells. The histologi-
cally most common glioma in children is astrocytoma.
7.1.1. Low-grade gliomas in children
The most common LGG in children are: pilocytic astrocytoma—PA (grade I), diffuse astrocy-
toma (grade II), oligodendroglioma (grade II), subependemal giant astrocytoma (SEGA) and 
pleomorphic xanthastrocytoma (PXA). The prognosis of LGG in children is relatively good, 
especially in well-defined grade I lesions with the possibility of total resection. Dissemination 
within the CNS is rare, but may be multifocal, especially in patients with neurofibromato-
sis type 1 syndrome [22]. Unfavorable prognostic factors include: low age, impossibility of 
total resection, diffuse growth (especially IDH mutated), diencephalic syndrome, presence of 
symptoms of intracranial hypertension and metastasis [23].
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7.1.1.1. Pilocytic astrocytoma WHO grade I
This tumor is the most frequent LGG in children (up to 85%). Typical localizations are: cer-
ebellum, diencephalon, optic tract, basal ganglia or brain stem [3]. Various localizations of this 
tumor also have their typical genetic characteristics. Its autosomal dominant forms are part 
of NF type 1 syndrome and tuberous sclerosis with typical localization over the course of the 
optical pathway, less often in hypothalamus. However, sporadic forms are more frequent. 
It may contain a BRAF-KIAA fusion that is connected to better prognosis. Conversely, the 
higher MIB-1 proliferation index is associated with shortened survival [24]. Therapy consists 
of surgical treatment. Despite the limited growth and the benign nature, the possibility of its 
removal is sometimes limited by its localization.
Its subtype is a pilomyxoid astrocytoma with a typical angiocentric array of myxoid matrix. 
It is most common in infants and children of pre-school age with a typical hypothalamus 
and chiasm localization. Due to its localization, total resection is less probable and thus has a 
slightly worse prognosis compared to pilocytic astrocytoma [25].
7.1.1.2. Diffuse gliomas WHO grade II
Diffuse low-grade gliomas account for 10% of all LGG in children [3]. Histologically, most 
common types are: astrocytoma, oligodendroglioma and mixed oligoastrocytoma. The most 
frequent group is the diffuse astrocytoma (DA), which is mainly located in hemispheres (espe-
cially in the frontal and temporal lobe), brain stem, optic pathway, hypothalamus and thalamus. 
Although they may appear to be similar to diffuse gliomas of adulthood, they have different 
genetic characteristics and typical biological behavior. Unlike DA of adulthood, for which the 
presence of IDH1 and IDH2 mutations is typical, these are very rare in children. MAPK pathway 
and BRAF gene alterations are more common [26]. Unlike diffuse adult LGG, DA of pediatric 
type usually do not undergo malignant transformation into higher grade glioma, so their prog-
nosis is more favorable. Especially in older children it is important to provide genetic diagnostics 
of the tumor type and differentiation between the more favorable type of LGG (DA without IDH 
mutation or diffuse oligodendroglioma without IDH mutation and 1p/19q co-deletion) and adult 
LGG type that may occur in older children and adolescents [27]. Up to 75% of adult LGG types 
in childhood are subject of malignant transformation. Treatment consists of surgical removal of 
the tumor and subsequent observation, but their infiltrative growth pattern generally does not 
allow their total resection. In case of relapse and progress in tumor growth, chemotherapy with 
carboplatin (with or without vincristine) may be used. Alternatively, the TPCV regimen (thio-
guanine, procarbazine, lomustine and vincristine) may be used, rarely in the second line with 
vinblastine and temozolomide. In relapsing non-responding tumors, bevacizumab is given in 
combination with irinotecan [28] and in some cases accompanied with radiotherapy. For early 
and late side effects of radiation, chemotherapy is preferred in children (in opposite to adult 
treatment). In pediatric patients, tumor localization and age at diagnosis are stronger factors for 
choosing therapy modality than the histological characteristics of the tumor itself [29, 30].
7.1.1.3. Subependymal giant cell astrocytoma WHO grade I
This tumor type is most frequently diagnosed in patients with tuberous sclerosis and mutations 
in TSC1 and TSC2 genes. Its typical location is a lateral ventricle, mostly growing subependymal 
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near the foramen Monroi [6]. Growth pattern is slow without infiltration of surrounding tis-
sues. Surgical resection, if possible, is a modality of choice in treatment of this tumor. SEGA is 
one of few tumors with proven efficacy of targeted treatment with mTOR inhibitors, everoli-
mus or sirolimus, which may also eliminate the necessity of surgical treatment [31].
7.1.1.4. Pleomorphic xanthoastrocytoma WHO grade II
PXA is relatively rare tumor, which accounts for 0.5–1% of all CNS tumors in childhood [3], 
typically occurring supratentorially, especially in the temporal lobe. It grows in the cortex, 
sometimes infiltrating meninges [6]. The most common symptoms are epileptic seizures. 
Frequently, V600E mutation of the BRAF gene occurs, especially in temporal lobe localization 
[32]. This tumor may undergo malignant transformation into an anaplastic form, which is 
classified as a separate type of tumor in the new WHO classification, has grade III and belongs 
to the HGG. Like grade II pleomorphic xanthastrocytoma, it often shows a V600E mutation 
of the BRAF gene [33].
7.1.2. High-grade gliomas in children
High-grade gliomas account for 15–20% of all pediatric CNS tumors [3]. HGG in children 
include anaplastic astrocytoma (grade III), glioblastoma and its variants (grade IV) and 
diffuse gliomas of midline structures (including diffuse pontine glioma). They are charac-
terized by very high mitotic activity and in grade IV also with presence of microvascular 
proliferation and necrosis as it is in adult HGG. Despite these common histological features, 
children’s HGG differ from adult tumors by their typical localization, genetic alterations and 
clinical behaviors. Pediatric HGG almost always grow as primary malignancies and their 
malignant transformation from LGG is extremely rare [34]. Besides localization in cerebral 
hemispheres, which is also typical for adult forms of HGG, pediatric HGG occur more often 
in midline structures, such as thalamus, cerebellum or pons. Pontine HGG are typical for 
pediatric age group (account for 50% of all HGG in children) and have even worse prognosis 
than hemispheric tumors [35]. Children’s HGGs (especially tumors in children under 3 years 
of age) have significantly less genetic alterations than adult forms [36]. On the basis of a recur-
ring combination of genetic and epigenetic features and characteristic biological and clinical 
behavior, 6 subtypes of HGG were determined (Table 1).
The K27 subtype is characteristically found in pons, thalamus and cerebellum in younger 
children. Its typical alterations are: mutation of K27, TP53 and ATRX genes, PDGFRA ampli-
fication, ACVR1 mutation (typical for localization in pons) and mutation of FGFR1 which is 
typical for thalamic site of tumor. Among all subtypes it has the shortest survival—from 6 to 
9 months [37, 38].
The G34 subtype is more frequent in adolescents and young adults and typically grows in 
cerebral hemispheres. It most commonly contains mutations of the G34, TP53 and ATRX 
genes. The survival time is about 1 year after the diagnosis is determined [37].
The IDH subtype with typical IDH1, IDH2, TP53 and ATRX mutations, grows usually in the 
hemisphere. Tumors with IDH mutations account for less than 10% of children’s HGG, they 
occur more commonly in adults. This type can also arise from malignant transformation of 
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Type K27 G34 IDH RTK-I Mesenchymal Epitheloid
Age Young child Adolescent Adolescent All Adolescent Young child
Typical 
location










mut. K27, TP53, ATRX, ACVR1 
(pons), FGFR1 (thalamus), 
ampl. PDGFRA
H3.3, mut. G34, 
TP53, ATRX
mut. IDH1, IDH2, 
ATRX, TP53
ampl. PDGFRA, EGFR, 
mut. TP53, del. CDKN2A/
CDKN2B
mut. NF1, TP53, ampl. 
PDGFRA, EGFR, del. 
CDKN2A/CDKN2B




Proneural Mixed Proneural Proneural Mesenchymal Unknown
Median 
survival
6 months 1 year >2 years 1 year 1 year >4 years
Mut., mutation; ampl., amplification, del., deletion [38].
Table 1. Characterization of pediatric HGG subtypes.
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LGG, what is generally rare in children. According to prognosis, this type belongs to more 
favorable subtypes with a survival period of more than 2 years [34, 38].
The RTK-I (receptor tyrosine kinase inhibitor) subtype grows in cerebral hemispheres 
and occurs throughout the pediatric age spectrum. Typically, it includes: amplification of 
PDGFRA and EGFR, TP53 mutation and CDKN2A/CDKN2B deletion. Patients with this tumor 
subtype have a worse prognosis of survival, generally within 1 year [36, 38].
Mesenchymal subtype is most common among adolescents and young adults. It also occurs 
in cerebral hemispheres and contains mutations of NF1 and TP53, amplification of PDGFRA 
and EGFR and deletion of CDKN2A/CDKN2B. It also belongs to worse types according to 
prognosis, with a survival of up to 1 year [36, 38, 39].
The last subtype is epithelioid glioblastoma which is similar to pleomorphic xanthoastro-
cytoma. It grows in cerebral hemispheres, in younger children and typically displays BRAF 
V600E mutation and CDKN2A deletion. It belongs to most favorable subtypes with a survival 
of more than 4 years [6, 12].
The presence of oncogene amplification, such as MYCN, PDGFR and EGFR, is associated with 
a worse prognosis in all types [40]. The most important prognostic factor is histological tumor 
grading and the extent of surgical resection. Radiotherapy is used in subsequent oncological 
treatment. Its combination with chemotherapy with temozolomide is therapeutically less suc-
cessful than in adults [35]. Lomustine, vincristine and prednisone may also be used in chemo-
therapy. In case of recurrent HGG, repeated resection is considered individually, depending 
on the histological nature of the original tumor, the recurrence localization or the length of 
the progression free period. Reoperation could be also necessary for obtaining of fresh tis-
sue samples for targeted treatment or for local administration of chemotherapy. In patients 
whose initial treatment failed, high-dose chemotherapy with total bone marrow suppression 
and subsequent hematopoietic stem cell transplantation [41] or clinical trial of new treatment 
modalities may be attempted. Molecular targets are very limited. Patients with BRAF V600E 
mutation are tested for BRAF inhibitors (vemurafenib and dabrafenib) with partial effect [19].
7.1.2.1. Diffuse midline glioma, H3 K27 M-mutant
The previous WHO classification is also called diffuse intrinsic pontine glioma (DIPG). 
The new edition classifies this tumor as diffuse midline glioma because it also appears in 
thalamus, cerebellum and spinal cord. It is predominantly considered childhood tumor, 
although it may also occur in adults. It contains a typical K27 M mutation of the histone 
H3 gene H3F3A (less frequently the HIST1H3B gene) and grows typically diffusely and 
infiltrates surrounding tissues [37]. It is classified as WHO grade IV, regardless of the pres-
ence or absence of anaplastic features [12]. A tumor growing in the ventral pontine region 
is a highly aggressive, destructive neoplasm that accounts for up to 80% of all glioma in 
the brain stem of children. The mean age at diagnosis is 6–7 years and median survival 
is 9 months [42]. Cranial nerve lesions, long-tract lesion symptoms, ataxia and behavioral 
disorders appear as leading clinical symptoms. The first symptom is often the abducens 
nerve palsy, which is also a negative prognostic factor. Also facial nerve palsy may occur. 
Obstruction of CSF pathways could lead to hydrocephalus [43]. Typically, on MR image 
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tumor occupies more than half of the axial diameter of the pons. It has no exact board-
ers and does not enhance after gadolinium administration. Due to the typical MRI image 
and its localization, biopsy is rarely indicated, but in some cases stereotactic biopsy could 
be beneficial [44]. This tumor is known to spread to the distal parts of the brain stem and 
along the white matter tract to both the cerebellum and the thalamus in over half of the 
patients. Supratentorial spreading and leptomeningeal dissemination are uncommon [39]. 
Total resection due to its localization and growth pattern is not possible, so the most com-
mon treatment is radiotherapy, which helps to control symptoms and generally prolongs 
patient’s survival. Because of the known CNS spread, irradiation of the entire head or the 
entire neural axis is sometimes chosen [39]. Systemic administration of chemotherapeutic 
agents has been shown to be ineffective for insufficient passage through the hematoence-
phalic barrier to pons [45]. The administration of chemotherapy (especially topotecan) is 
also attempted locally, directly to the tumor, using a stereotactic catheter. However, the 
results are not yet clear [46]. Children under age of 3 have a slightly better prognosis, prob-
ably due to different molecular genetic characteristics [47].
7.1.3. Ependymomas
Ependymomas are tumors originating from ependymal cells, which form a lining of CSF 
pathways and produce cerebrospinal fluid. They form the second most common group of 
children’s CNS malignancies. They occur supratentorially, in the posterior fossa and in the 
spinal cord, mostly in children under 10 years of age [48]. Clinical signs depend on localiza-
tion. In the most frequent, infratentorial localization, they present with the development of 
obstructive hydrocephalus, ataxia, cervical spinal pain and symptoms of cranial nerve lesion 
can also be present. Supratentorial localization often causes headaches, epileptic seizures and 
depending on localization, the development of focal neurological deficit. In case of suspicion 
on ependymoma, it is necessary to realize the MRI of whole craniospinal axis even before 
surgery. If possible, lumbar puncture with CSF sampling is recommended.
Ependymomas could be histologically: subependymoma (grade I), myxopapillary epen-
dymoma (grade I), ependymoma (grade II), ependymoma, RELA fusion-positive (grade 
II—III) and anaplastic ependymoma (grade III). Subependymoma and myxopapillary epen-
dymoma appear almost exclusively in adults. The existence of several molecular subtypes of 
ependymomas, which differ in their localization, molecular genetic characteristics, typical age 
group of patients and prognosis, are known.
Two genetically distinct subgroups are distinguished in ependymomas of posterior fossa 
localization [49]. Group A occurs more frequently (up to half the ependymomas of all local-
izations) affecting predominantly younger children (3 years of age) and has a worse progno-
sis. In these tumors, fewer gene alterations occur and the VEGF, PDGFR, integrin and MAPK 
signaling pathways are most commonly affected [50]. Epigenetic suppression of differentia-
tion genes is often present in this group of tumors [51]. Duplication of 1q occurs in 25% of 
group A ependymomas and it is a common negative prognostic feature [52]. Less frequently 
occurring group B affects predominantly adolescents and young adults. It contains frequent 
chromosome changes and its prognosis is more favorable than in group A. In both groups, the 
mutation rate is relatively low and gene mutations occur sporadically [50].
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Up to 70% of supratentorially localized ependymomas harbor fusion of C11orf95-RELA on 
chromosome 11q [50]. This change never occurs when locating in the posterior fossa. The dis-
covery of the presence of this fusion was so significant that in the new WHO classification of 
brain tumors from 2016 the ependymoma with the RELA fusion was classified as a separate 
entity [12]. Homozygous deletion of CDKN2A with or without the presence of duplication of 
1q is a negative prognostic factor [53]. The most frequent occurrence is in children with an 
average age of 8 years. The fusion of YAP1 (with MAMLD1 or FAM118B) occurs in supra-
tentorially localized ependymomas without RELA fusion. These tumors are more common in 
younger children with an average age of 1.4 years. From all ependymomas, the worst prog-
nosis has supratentorial RELA positive tumors and group A ependymomas in the posterior 
fossa. At the same time, they are the most common forms (together make up two-thirds of all 
ependymomas) that occur predominantly in children [53].
Therapeutic modality is extensive surgical removal followed by radiotherapy, which can only 
be used in the treatment of children aged more than 1 year. Currently, the use of chemotherapy 
(especially vincristine, cyclophosphamide, cisplatin and etoposide) is in clinical trials [38]. The 
choice of the treatment scheme determines the age of the child, the histological type of tumor, 
the extent of the resection performed and the presence of dissemination in the CSF pathways.
7.2. Neuronal and mixed neuronal-glial tumors
It is a heterogeneous group of tumors with neuronal or mixed neuroglial morphology. They 
are mostly grade I, but their anaplastic forms can also occur. Following tumors are most fre-
quently present in children.
7.2.1. Desmoplastic infantile astrocytoma (DIA) and ganglioglioma (DIGG)
These grade I tumors account for 0.5% of CNS childhood tumors [3]. They occur almost exclu-
sively in children under 2 years of age. MRI verifies a large cystic tumor, especially in the 
frontal or parietal lobe. They are histologically and genetically almost identical, the only dif-
ference between them is the neoplastic neuronal component. Approximately 40% of these 
tumors display MET amplification and about 10% also BRAF V600E mutation [54].
7.2.2. Ganglioglioma (GG)
These tumors are characterized by a combination of neoplastic ganglion cells with a glial com-
ponent similar to PA or diffuse glioma (especially astrocytoma). They occur mainly supraten-
torially. Seizures are usually leading symptom [33]. GG often harbor BRAF V600E mutation. 
The glial component of GG can undergo malignant transformation to anaplastic form that 
has higher mitotic activity, endothelial proliferation and necrosis in 3–5%. Up to half of the 
anaplastic GG is characterized by the presence of the BRAF V600E mutation, a minor part of 
the TP53 mutation [6].
7.2.3. Dysembryoplastic neuroepithelial tumor (DNET)
It is a low-grade tumor (grade I), which occurs mainly supratentorially in the temporal lobe. 
It often manifests as drug-resistant epilepsy. There are several histological subtypes, which do 
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not differ in typical age of origin, the nature of epileptic seizures or prognosis. Most of these 
tumors show alterations of FGFR1 and BRAF V600E mutation [27].
7.3. Embryonal tumors
This group of tumors originates from embryonal cells that remain present in the CNS after 
birth. They are the most common childhood malignant CNS tumors (15–20%) in children under 
the age of 14 [12]. In adults, they are extremely rare. Most frequently occurring embryonal 
tumors are: meduloblastoma, atypical teratoid/rhabdoid tumor and CNS embryonal tumors 
(better known under the older name CNS primitive neuroectodermal tumors—PNETs). All 
tumors of this group tend to spread along the CFS pathways. Therefore, it is recommended to 
perform MR of whole craniospinal axis prior to surgery. CSF sampling is also indicated, as the 
finding of circulating tumor cells can appear earlier than dissemination in MRI. The prognosis 
of embryonic tumors depends on the age of the patient, dissemination of the tumor within 
CNS at the time of diagnosis, the size of the postoperative residue and on the histopathologi-
cal and molecular biological properties of the tumor.
7.3.1. Medulloblastoma (MB)
It is the most common malignant brain tumor type in children. MB is a group of lesions that 
differ significantly by their genetic alterations, histological features and prognosis. In all cases, 
however, they are grade IV and fast-growing. Characteristic localization is infratentorial and 
leptomeningeal spread is typical. MB often manifests by symptoms of intracranial hyperten-
sion and blockage of CSF pathways as well as other symptoms, such as ataxia and nystagmus. 
Medulloblastoma may also occur as part of hereditary syndromes: Turcot, Rubinstein-Taybi, 
Gorlin, Li-Fraumeni syndrome and Fanconi anemia. There are four histological variants 
(classic type, desmoplastic nodular type, medulloblastoma with extensive nodularity and 
large cell and anaplastic type) and four subtypes depending on the signal pathway involved 
or genes altered: WNT (10%), SHH (30%), group 3 (15%) and group 4 (45%). WHO classi-
fication of brain tumors from 2016 classifies genetically defined MB into: WNT-activated, 
SHH-activated and TP53-mutant, SHH-activated and TP53-wildtype and non-WNT/non-SHH 
medulloblastoma, which is divided into MB group3 and MB group 4 [12].
The WNT medulloblastoma is the less frequent group (10%), which is typically found in 
the brain stem area in children aged 10. Often displays classic histology. The incidence of 
CNS metastases is very low. Activation of the WNT signaling pathway is characteristic [55]. 
About 90% of these tumors present with CTNNB1 mutation. Mutations of DDX3X, chromatin 
remodeling genes and TP53 are also common. TP53 mutation in this type of tumor is not asso-
ciated with a worse prognosis as it is in TP53 mutated SHH MB. In general, WNT-activated 
MB has a very good prognosis.
The SHH group of medulloblastomas accounts for 30% of all MB and is the most heteroge-
neous. All histological types could occur. Dominant localization is in cerebral hemispheres. 
The most commonly affected age group is up to 4 years of age and then adolescents over 
17 years of age. In children up to 4 years of age, it is most commonly present MB with exten-
sive nodularity and in group 4–17 years of age, it is classic and large cell anaplastic type. 
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Desmoplastic nodular type is typical for patients over 17 years of age [56]. Genetic alterations 
also vary by age category. Mutation of SUFU gene is commonly present in age group up to 
4 years, whereas SMO mutation occurs mainly in patients over 17 years of age. Between 4 
and 17 years of age, amplification of MYCN and GLI2 occurs. PTCH1 alterations and TERT 
promoter mutation occur in all age categories [57]. While MBs of children under 4 years with 
extensive nodularity generally have a better prognosis, MBs with large cell anaplastic charac-
teristics, presence of MYCN amplification or TP53 mutation are very aggressive. They tend to 
metastasize within the CNS, and therefore are associated with a very poor prognosis [55, 56]. 
SHH-activated MBs with TP53 mutation are classified separately. In children with TP53 muta-
tion, it is often a germline mutation that is part of the Li-Fraumeni syndrome [58].
Non-WNT/non-SHH MB is divided into group 3 and group 4. While group 3 forms 15%, 
group 4 45% of all MBs. Although genetically different, some characteristics and genetic alter-
ations are common. There is a higher occurrence in boys in both groups, structural anomalies 
are common—especially the formation of isochromosome 17q. A structural alteration that 
aberrantly induces the activity of GFI1 or GF1B proto-oncogenes is common in both groups, 
particularly in group 3 [59]. The worst prognosis of all types has group 3 (particularly in 
boys), with large cell anaplastic morphology and with proven MYC over-expression and 
amplification. Group 4 is the most common molecular type with a pronounced predominance 
in boys. Nearly all tumors in this group have classic morphology. The prognosis of patient 
survival is moderate—except those with proven MYC amplification, which have worse prog-
nosis [55]. Patients with metastasis present at diagnosis have a high risk of relapse, with the 
exception of patients with isochromosome 17, who make up a subgroup with more favorable 
prognosis [60].
The diagnosis is based on preoperative MRI examination of the craniospinal axis. Over the 
past 30 years, the most fundamental shift has been made in treatment of MB among all CNS 
childhood tumors and has changed from a fatal disease to a tumor with a 70% curability. The 
basis is surgical treatment with the maximal possible extent of resection. In the postoperative 
period, MRI is again indicated to evaluate the postoperative residue and the examination of 
cerebrospinal fluid is also beneficial. Medulloblastoma has as one of the few CNS tumors 
staging system that has 5 degrees (M0 = not disseminated, M1 = positive cytology of CSF 
without MR image of dissemination, M2 = nodular proliferation in cerebellar and cerebral 
subarachnoid spaces and in ventricles, M3 = nodular proliferation in spinal subarachnoid 
spaces, M4 = extra-neural propagation). Surgery is followed by chemotherapy and radiother-
apy with whole CNS irradiation for frequent dissemination of medulloblastoma within the 
CNS. The chemotherapy regimens use either a combination of cisplatin, lomustine and vin-
cristine or a combination of cisplatin, cyclophosphamide and vincristine [61]. Radiotherapy 
is administered at a dose of 54 Gy targeted to the tumor bed, followed by irradiation of the 
craniospinal axis at a dose of 24–36 Gy. The introduction of chemotherapy into the treatment 
scheme reduced the dose necessary to irradiate the craniospinal axis, thereby reducing the 
incidence of side effects of radiation [62]. However, radiotherapy in children under 3 years 
of age is not used for serious adverse effects on brain development. To potentiate the effects 
of standard chemotherapy, methotrexate is concomitantly administered to children under 
3 years, either systemically or locally [63].
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7.3.2. Atypical teratoid/rhabdoid tumor (AT/RT)
This high-grade neoplasm (grade IV) accounts for 1–2% of pediatric CNS tumors. Typically, 
it occurs in the age category up to 5 years, and in children under 1 year of age, it is the most 
common malignant CNS tumor. As it grows very quickly, clinical manifestations occur early. 
AT/RT is often localized supratentorialy and also in the posterior fossa [3, 64]. About 20% 
of patients have already dissemination of the tumor at the time of diagnosis, usually along 
leptomeninges. Rare coincidence with renal tumors may occur [65]. Genetically, it is charac-
terized by deletion on the 22nd chromosome and loss of INI1/SMARCB1/BAF47 expression 
due to germline or somatic mutations. Evaluation of SMARCB1 expression is necessary to 
distinguish AT/RT from other embryonic tumors [66]. This tumor was the first primary CNS 
tumor in which the major tumor suppressor gene was identified, namely SMARCB1. The 
presence of SMARCB1 germline mutation is the basis for identifying the syndrome predis-
posing to the rhabdoid tumor, which is common in patients with coincidence of AT/RT with 
rhabdoid tumor of the kidney. The greatest risk of developing tumors in this syndrome is 
during the first year of age, which requires monitoring and active screening in children from 
these families. Immunohistochemical evidence of cytokeratin, epithelial membrane antigen, 
glial fibrillary acidic protein, synaptophysin, desmin and vimentin is also necessary. The 
MIB-1 proliferation index is high, 50–100% [67]. MRI of the entire craniospinal axis as well 
as examination of CSF for the presence of tumor cells is useful in diagnosis. There is no stan-
dard treatment regime for AT/RT. Treatment is based on surgical resection. The localization 
of the tumor and the extent of its spread is crucial for the choice of treatment modalities. 
Prolongation of survival requires a combination of postoperative systemic and intrathecal 
chemotherapy (methotrexate, cytarabine and hydrocortisone) with radiotherapy. Negative 
prognostic factors include: the presence of SMARCB1 germline mutations, postoperative resi-
dues, dissemination at the time of diagnosis and the age under 2 years [64].
7.3.3. Embryonal tumor with multilayered rosettes, C19MC-altered (ETMR)
This tumor typically occurs in children under 3 years of age. It has a poor prognosis, most 
patients die within 1–2 years after diagnosis [68]. Characteristic is the 19q13.42 locus amplifica-
tion, which contains a cluster of microRNA (C19MC) and a fusion between TTYH1 and C19MC 
[69]. Treatment begins with a surgical resection, followed by adjuvant oncology treatment with 
chemotherapy and radiotherapy. In children under 3 years, radiotherapy is not indicated.
7.3.4. Neuroblastoma and ganglioneuroblastoma CNS
These two neoplasms belong to embryonal tumors but show neuronal differentiation, in the 
case of ganglioneuroblastoma also the presence of ganglionic cells. They most often occur in 
early childhood. In general, neuroblastomas are a frequent diagnosis, but especially in the 
chest and abdominal cavity (in the brain they are rare). Some of these include gene alterations 
leading to increased expression of the transcription factor FOXR2 [70]. The treatment scheme 
is the same as for other embryonal tumors – surgery followed by chemotherapy in children 
less than 3 years of age and addition of radiotherapy in older children.
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7.4. Pineoblastoma
In the past, this tumor was classified as embryonal, but in the new WHO classification it 
was reclassified to a group of pineal tumors. Its histological and molecular biological proper-
ties are similar to embryonal tumors. Because of its location, obstructive hydrocephalus is 
predominantly caused by blockage of CSF passages at the level of the third ventricle, and 
symptoms of the pressure on tectum—especially oculomotor disorder, poor reaction of pupils 
to light with present reaction to accommodation, later hemiparesis and ataxia. Often occur 
germline mutations of the RB1 and DICER1 genes [71]. Pineoblastoma is often found in chil-
dren with congenital retinoblastoma. It can rarely disseminate along CSF pathways. A stag-
ing system similar to embryonal tumors is used. The primary therapeutic step is surgical 
resection. However, due to localization, total resection is unlikely, with only partial resection 
or biopsy performed in the majority of patients. This is followed by oncological treatment that 
combines chemotherapy and radiotherapy with a dose of 54 Gy on tumor bed and 24–36 Gy 
for craniospinal axis. A different therapy management is used in children under 3 years of 
age who undergo biopsy, followed by chemotherapy or high-dose chemotherapy with bone 
marrow ablation followed by hematopoietic stem cell transplantation.
7.5. Germ cell tumors
Intracranial germ cell tumors are a heterogeneous group that accounts for 3–4% of brain 
tumors with the exception of Japan where the incidence is higher, up to 15% [72]. Based on 
histopathological characteristics, they are divided into germinomas and nongerminomas 
(embryonal carcinoma, choriocarcinoma, mature or immature teratoma, teratoma with malig-
nant transformation, yolk sac tumor and mixed germ cell tumor). In some countries, divid-
ing into secretory and non-secretory tumors is also used—depending on the presence and 
absence, respectively, of elevation of serum and CSF tumor markers [12].
The most common localization is the pineal and suprasellar area, where they form either soli-
tary or multiple lesions. The pineal region is much more frequent, but up to 10% of patients 
have both sites at the time of diagnosis, which is typical for pure germinomas [73]. Rare locali-
ties include basal ganglia, brain ventricles, cerebral hemispheres and thalamus. Tumor in the 
suprasellar region is often presented by hormonal expression. Often occur diabetes insipidus, 
enuresis, anorexia and also psychological changes [74]. Pineal localization has usually earlier 
manifestation, with hydrocephalus and diplopia developing from pressure to the tectal and 
aqueductal region. The most common germ cell tumor is germinoma. Mutations of the KIT, 
KRAS and NRAS genes are common [75]. Half of germinoma cases harbor deregulation of 
the KIT/RAS and AKT/mTOR pathways. The germline variations of JMJD1C occur more fre-
quently in Japanese, which is probably related to the higher incidence of germinomas in this 
country. This gene is important for maintaining male germ cells [76].
In the diagnosis, apart from MRI, cytological examination of CSF and evaluation of alpha-
fetoprotein (AFP) and beta human chorionic gonadotropin (bHCG) concentrations in both 
serum and in CSF is used [77]. In addition, hormonal examination of hypothalamic and pitu-
itary function and examination of the visual field in suprasellar and hypothalamic tumors are 
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necessary. The essentials of the treatment are chemotherapy and radiotherapy, but biopsy is 
required for reliable diagnosis. Only in tumors with unambiguous MRI image and positive 
tumor markers in CSF can be treated without biopsy.
7.6. Choroid plexus tumors
These rare intraventricular tumors account for 1% of all brain tumors and 2–4% of pediatric 
tumors. They arise from neuroectoderm and consist of differentiated epithelial plexus cells 
that produce CSF. They most often occur in the age group under 2 years of age. The most com-
mon site are lateral ventricles (less often the 3rd and 4th ventricle), but could also occur in the 
cerebellopontine angle and in the cerebral parenchyma. They mostly manifest by symptoms of 
intracranial hypertension from hydrocephalus, both from overproduction of the CSF as well as 
from obstruction of the CSF pathways. Sometimes, however, they can also manifest suddenly, 
in case of bleeding into the tumor [78]. This group of tumors consists of: choroid plexus papil-
loma (grade I), atypical choroid plexus papilloma (grade II) and choroid plexus carcinoma 
(grade III). There are no genetic differences between papilloma and atypical papilloma. In 
both, immunoreactivity to cytokeratin, vimentin, S100 protein and synaptophysin is present. 
On the other hand, carcinoma is genetically different. The germline mutations of TP53 as part 
of the Li-Fraumeni syndrome predispose to the formation of plexus carcinoma. Somatic TP53 
mutations are present in up to 60% of the plexus carcinomas and the more copy of the mutated 
TP53 is present, the worse is the prognosis [79]. Chromosome alterations are rarely detected.
MRI showing relatively well-defined extra-axial mass that does not invade the brain tissue 
with gadolinium enhancement and containing calcification and microhemorrhages is essential. 
Surgical treatment is the method of choice. Due to the rich vascular supply, preoperative tumor 
embolization is preferred in some cases. Hydrocephalus treatment is also necessary—some-
times requires external ventricular drainage. In some patients hydrocephalus is permanent, and 
therefore ventriculoperitoneal shunt or the endoscopic ventriculostomy of the 3rd ventricle are 
required [80]. There is no need for further treatment in the papilloma, radiotherapy, radiosurgery 
or chemotherapy with bevacizumab may be used in atypical or recurrent forms. Chemotherapy 
has been proven in choroid plexus carcinoma, which can spread along CSF pathways [81].
7.7. Craniopharyngioma
Craniopharyngiomas are rare tumors, accounting for 3–5% of pediatric brain tumors. They 
occur in two subtypes: adamantinomatous and papillary [12]. The adamantinomatous variant 
for which the CTNNB1 mutation is typical, is often found in children [6]. Their congenital origin 
is assumed to be from the ectodermal residues of the Rathke capsule or from another embryonal 
epithelium. They most commonly occur in the suprasellar area with intrasellar propagation. 
Symptoms include: endocrine disorders, visual disturbances, hydrocephalus symptoms and 
very rarely when growing in the posterior fossa—headache, diplopia, ataxia and hearing loss 
[82]. The diagnosis is made by MRI that displays a tumor with a solid and cystic component 
and with intratumoral calcifications. Evaluation of hormonal function and visual field is also 
necessary. The therapy of newly diagnosed craniopharyngiomas is a combination of surgical 
treatment, radiotherapy and a drainage of the cyst. The prognosis is good, 90% of patients sur-
vive more than 10 years [83]. Total resection may have serious complications, including: need 
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for hormone replacement therapy, severe obesity, behavioral disorders, blindness, epileptic 
seizures, postoperative CSF leak, pseudoaneurysms, oculomotor disorders, severe postopera-
tive bleeding and hypothalamic injury [84]. While recurrent craniopharyngiomas are treated 
by resection, radiotherapy or radiosurgery, tumors with unresponsive cystic component can 
be treated by administration of P32, bleomycin or interferon alpha directly into the tumor bed. 
It can be supplemented by systemic administration of interferon [85].
7.8. Other pediatric CNS tumors
Schwannomas are in children rare, mostly benign neoplasms originating from Schwann cells 
of cranial or other nerves. Some of these tumors are present as a part of the NF2 type genetic 
syndrome, especially at bilateral occurrence. From cranial nerves, this tumor mostly affects 
VIII cranial nerve and is called vestibular schwannoma or acoustic neurinoma [86]. Vestibular 
schwannomas can cause loss of hearing and tinnitus. Diagnosis is mainly based on MRI. The 
method of choice is resection of the tumor, further treatment is usually not necessary. In rare 
cases, radiotherapy can be used in the presence of postoperative residues [87].
Meningiomas that grow from meninges are much rarer in children than in adults—they 
account for about 2.6–2.9% of CNS childhood tumors [2]. It occurs most often between 6 and 
12 years of age. Children have a higher incidence of tumors growing from the skull base and 
a higher incidence of atypical (grade II) and anaplastic (grade III) meningiomas compared to 
adults. Chromosome 22 abnormalities are often present, also as a part of the NF2 type syn-
drome. Tumors connected with NF2 occur at younger age (about 2 years) and may also be the 
first symptom of this disease. In benign tumors, surgical treatment is largely sufficient, but 
in the case of incomplete resection and in tumors of higher grade, is usually combined with 
radiotherapy. Favorable prognostic factors include: age up to 10 years, superficial localiza-
tion, total extirpation and absence of NF2 syndrome, where localization and resection extent 
are stronger predictive factors than histological grade [88].
Primary CNS lymphomas (PCNSL) are rare in children. Patients with immunodeficiency have 
an increased risk of developing CNS lymphomas [89]. They occur mainly in children around 
14 years of age with moderate predominance in boys [90]. They are mostly localized in brain 
hemispheres. Clinical symptoms include symptoms of increased intracranial pressure, ataxia, 
hemiparesis, epileptic seizures and cranial nerve palsy. MRI and CSF sampling is used in 
diagnostics. MRI verifies solid lesion (even with a possible cystic component). Histologically, 
mature aggressive B cell lymphoma (B-NHL), as well as anaplastic large cell lymphoma 
(ALCL) or peripheral T cell lymphoma (PTCL) are most often present. Pediatric B-NHL has a 
low to moderate proliferation index, a lower Bc12 protein expression and a higher frequency 
of the Bc16 + GC fetal center phenotype, indicating a better prognosis [91]. While the progno-
sis of PCNSL in adults is very poor, in children is better. Interestingly, localization of PCNSL 
in deep brain structures does not affect the prognosis [90]. In chemotherapy, methotrexate or 
cytarabine at high doses are mostly used, usually providing satisfactory remission without 
need for use of radiotherapy (often used in ALCL form). It has been found that the exclusive 
use of chemotherapy is more effective than combined chemoradiotherapy. Explanation could 
be the use of lower doses of chemotherapy in combined therapy. High-dose therapy of metho-
trexate, which appears to be the most effective, is better tolerated by children compared to 
adults. Radiotherapy is therefore reserved for recurrent forms [89].




Pediatric CNS tumors are diagnostic and therapeutic challenge. A lot of specialists are 
involved in their management: pediatricians, neurologists, neurosurgeons, radiologists, radi-
ation and clinical oncologists, endocrinologists and others. Due to the development of MRI 
and its techniques, use of invasive examinations is minimalized. Over the past decades, there 
has been a significant refinement of operational technologies, enabling the most extensive and 
yet safe resection of the tumor. Children CNS tumors are frequent, often with unfavorable 
prognosis. While in most malignant tumors the prognosis has not improved as hoped, in case 
of medulloblastoma there has been a significant survival prolongation during last decades. 
Undoubtedly, this is due to extensive research of the molecular genetic characteristics of 
tumors, which identified genetically defined subgroups of medulloblastoma with different 
treatment strategies. This change was also reflected in the new WHO classification, which also 
classifies medulloblastomas based on genetic alterations. Intense research also takes place 
in other tumor entities, where the discovery is yet about to come. Identifying molecular and 
genetic targets is the only possible way to target individualized therapy that appears both in 
treatment and in further prognosis improving in this age group as a key point.
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